Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$999.60
-0.7%
$939.86
$623.78
$1,133.95
$941.64B0.483.18 million shs948,907 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$530.80
-1.7%
$496.45
$265.00
$615.00
$12.28B-1.04346,787 shs79,688 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.55
-2.7%
$39.61
$35.12
$81.44
$198.71B0.7721.67 million shs8.81 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.80%+3.28%+9.10%-3.20%+40.58%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+4.05%+0.94%+2.84%+16.18%+90.87%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$999.60
-0.7%
$939.86
$623.78
$1,133.95
$941.64B0.483.18 million shs948,907 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$530.80
-1.7%
$496.45
$265.00
$615.00
$12.28B-1.04346,787 shs79,688 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.55
-2.7%
$39.61
$35.12
$81.44
$198.71B0.7721.67 million shs8.81 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.80%+3.28%+9.10%-3.20%+40.58%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+4.05%+0.94%+2.84%+16.18%+90.87%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3321.88% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.76
Moderate Buy$687.0029.43% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5647.16% Upside

Current Analyst Ratings Breakdown

Latest LLY, MDGL, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Boost Price TargetBuy$640.00 ➝ $709.00
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/7/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Set Price Target$649.00
5/7/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Lower Price TargetBuy$587.00 ➝ $578.00
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/6/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Reiterated RatingBuy$620.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.44$24.74 per share40.41$33.13 per share30.17
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.77N/AN/A$23.57 per share22.52
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.25$4.44 per share10.04$7.12 per share6.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1535.5222.581.1134.98%105.77%23.76%N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.80N/A56.83N/A-27.32%-50.15%-25.44%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.4512.954.1937.23%63.31%22.19%N/A

Latest LLY, MDGL, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 million
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
2/19/2026Q4 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$0.04-$2.57-$2.61-$2.57$310.36 million$321.08 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.69%+15.18%24.58%11 Years
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.93%+21.74%41.08%N/A

Latest LLY, MDGL, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.63
3.50
3.16
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.06 million19.00 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk: The First Fruits Of Labor
Best Healthcare Stocks to Buy in 2026
Novo Nordisk A/S (NVO) stock forecast and price target
Novo Nordisk: Why I Won't Upgrade
Omeros (OMER) Q1 2026 Earnings Transcript
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
2 Ways to Play the Big Pharma Patent Cliff (NVO)
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$999.60 -7.10 (-0.71%)
As of 12:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$530.80 -9.09 (-1.68%)
As of 12:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.55 -1.25 (-2.72%)
As of 12:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.